Management of insomnia disorder
Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, Koffel E, Khawaja IS, Ouellette J, Butler M, Kane RL, Wilt TJ
Record ID 32016000034
English
Authors' objectives:
To assess the efficacy, comparative effectiveness, and harms of treatments for insomnia disorder in the general adult population and older adults.
Authors' recommendations:
CBT-I or medical therapy with eszopiclone, zolpidem, and suvorexant improve global and sleep outcomes for insomnia disorder. Clinical significance, applicability, comparative effectiveness, and long-term efficacy, especially among older adults, are less well known. Effect sizes vary, and a large placebo response is sometimes observed. Observational studies suggest an association of hypnotics with infrequent but serious harms. FDA labels provide specific warnings and precautions for drugs approved for insomnia.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.effectivehealthcare.ahrq.gov/ehc/products/548/2163/Insomnia-report-151230.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Adult
- Azepines
- Hypnotics and Sedatives
- Pyridines
- Sleep Initiation and Maintenance Disorders
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.